Affectis Pharmaceuticals

Affectis Pharmaceuticals is a Martinsried, Germany-based biopharmaceutical company that discovers and develops novel drugs for central nervous system disorders, inflammatory diseases, and neurodegenerative conditions. The organization focuses on advancing treatments for depression and schizophrenia by targeting specific brain receptors, including its proprietary P2X7 antagonist program and clinical trials involving cimicoxib. Throughout its operational history, the biotechnology firm raised over 30 million euros in total venture funding, which included a 12 million euro financing round in 2006 and a 3.3 million euro Series D tranche. The enterprise secured financial backing from prominent institutional investors such as Life Sciences Partners, Aescap Venture, and KfW, while also establishing a notable licensing and co-development agreement with Merck Serono. Affectis Pharmaceuticals was founded in 2003 as a spin-off from the Max Planck Institute of Psychiatry by Florian Holsboer and Herbert Stadler.